By year’s end, the FDA may approve the first oral GLP-1 pill — a 25 mg daily dose of semaglutide (Wegovy) — for chronic weight management in adults with obesity or overweight and comorbidities. Based on the phase 3 OASIS 4 trial, the pill led to an average 13.6% weight loss over 64 weeks with a favorable safety profile, showing promise comparable to injectable GLP-1s.
Physicians are cautiously optimistic. While some predict high demand — especially among patients averse to needles or weekly injections — others note uncertainties around insurance coverage, adherence, and misuse risks. There’s also buzz around newer GLP-1s in development like Lilly’s orforglipron and Novo’s amycretin.